GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Redhill Biopharma RDHL · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.28

-13.08%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Redhill Biopharma — daily RDHL Delayed
Market value
$1.5m
Last close × shares
Volume
24.3k
Shares, 20 Nov 2026

About Redhill Biopharma

Its shares trade under the ticker RDHL. It has been listed since 7 January 2013. In the fiscal year to 31 December 2025, it reported revenue of $286,000 and a net loss of $429,000. At that date it held total assets of $25.3m and shareholders' equity of $4.3m.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.

Figures and description from our data supplier, not checked against the company's own report.

More about Redhill Biopharma →

Latest on Redhill Biopharma

Our reporting

We have not reported on Redhill Biopharma yet.

Next results

18 Mar 2027

Due on 18 Mar 2027. Analysts expect earnings of -474.29 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Redhill Biopharma's ticker?

Redhill Biopharma trades as RDHL on its US listing, under ISIN US7574681034.

What was Redhill Biopharma's last closing price?

0.28 on 20 Nov 2026. The figure is in USD and is never converted.

When does Redhill Biopharma next report results?

Results are expected on 18 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.